Literature DB >> 31229984

Jejunojejunal intussusception secondary to metastatic uveal melanoma after 11 years of remission.

Hifza Waheed Butt1, Sarthak Soin1, Faisal Ali1, Antoni Wojtkowski1.   

Abstract

Malignant cutaneous melanoma frequently metastasises to gastrointestinal tract, small bowel being the most common site likely due to its rich vascular supply. However, most common sites for metastatic uveal melanoma are the liver (93%), lung (24%), bone (16%), skin/subcutaneous tissue (11%) and lymph nodes (10%). 1 We present a case of 46-year-old man with jejunojejunal intussusception secondary to metastatic uveal melanoma status postbrachytherapy after 11 years of remission. We aim to highlight the rare occurrence of adult intussusception secondary to uveal melanoma after a prolonged period of remission. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastroenterology; general surgery; ophthalmology; small intestine

Mesh:

Year:  2019        PMID: 31229984      PMCID: PMC6605911          DOI: 10.1136/bcr-2019-229535

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  The association between host susceptibility factors and uveal melanoma: a meta-analysis.

Authors:  Ezekiel Weis; Chirag P Shah; Martin Lajous; Jerry A Shields; Carol L Shields
Journal:  Arch Ophthalmol       Date:  2006-01

2.  Epidemiological trends in uveal melanoma.

Authors:  Michael T Andreoli; William F Mieler; Yannek I Leiderman
Journal:  Br J Ophthalmol       Date:  2015-04-22       Impact factor: 4.638

3.  The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death.

Authors:  Tero Kivelä
Journal:  Br J Ophthalmol       Date:  2009-09       Impact factor: 4.638

4.  Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.

Authors:  Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Barbara S Hawkins; James A Hayman; Ishmael Jaiyesimi; Lee M Jampol; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Bradley R Straatsma; Jonni Thoma
Journal:  Arch Ophthalmol       Date:  2005-12

Review 5.  Uveal melanoma: trends in incidence, treatment, and survival.

Authors:  Arun D Singh; Mary E Turell; Allan K Topham
Journal:  Ophthalmology       Date:  2011-06-24       Impact factor: 12.079

6.  Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.

Authors:  Carol L Shields; Minoru Furuta; Archana Thangappan; Saya Nagori; Arman Mashayekhi; David R Lally; Cecilia C Kelly; Danielle S Rudich; Anand V Nagori; Oojwala A Wakade; Sonul Mehta; Lauren Forte; Andrew Long; Elaina F Dellacava; Bonnie Kaplan; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2009-08

7.  Incidence of uveal melanoma in Europe.

Authors:  Gianni Virgili; Gemma Gatta; Laura Ciccolallo; Riccardo Capocaccia; Annibale Biggeri; Emanuele Crocetti; Jean-Michel Lutz; Eugenio Paci
Journal:  Ophthalmology       Date:  2007-05-11       Impact factor: 12.079

8.  Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.

Authors:  Carol L Shields; Swathi Kaliki; Michael Livesey; Brianna Walker; Robert Garoon; Marissa Bucci; Eric Feinstein; Aline Pesch; Cristina Gonzalez; Sara E Lally; Arman Mashayekhi; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2013-08       Impact factor: 7.389

9.  Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study.

Authors:  S Thomas; C Pütter; S Weber; N Bornfeld; D R Lohmann; M Zeschnigk
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

10.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.

Authors:  J William Harbour; Elisha D O Roberson; Hima Anbunathan; Michael D Onken; Lori A Worley; Anne M Bowcock
Journal:  Nat Genet       Date:  2013-01-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.